Press coverage about Female Health Company (The) (NASDAQ:VERU) has trended somewhat positive on Wednesday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Female Health Company (The) earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.3917718780771 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Health and Nutrition Company for New and Expectant Mothers Looks to Grow (arlnow.com)
- Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results (finance.yahoo.com)
- Reviewing Taro Pharmaceutical Industries (TARO) & Female Health Company (The) (VERU) (americanbankingnews.com)
- Women Healthcare Market 2017 Amplifies Impressively; 5.04% of CAGR By 2023 (emailwire.com)
Several brokerages recently issued reports on VERU. HC Wainwright set a $5.00 price objective on Female Health Company (The) and gave the company a “buy” rating in a research report on Tuesday. ValuEngine upgraded Female Health Company (The) from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Rodman & Renshaw began coverage on Female Health Company (The) in a research report on Wednesday, July 26th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Zacks Investment Research upgraded Female Health Company (The) from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Wednesday, September 27th.
In other news, insider Mitchell Shuster Steiner purchased 100,000 shares of Female Health Company (The) stock in a transaction on Friday, September 15th. The stock was purchased at an average price of $1.63 per share, with a total value of $163,000.00. Following the transaction, the insider now directly owns 7,764,767 shares in the company, valued at approximately $12,656,570.21. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Harry Fisch purchased 34,250 shares of Female Health Company (The) stock in a transaction on Wednesday, September 13th. The shares were purchased at an average cost of $1.51 per share, with a total value of $51,717.50. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 146,975 shares of company stock valued at $234,279. Insiders own 10.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/15/female-health-company-the-veru-given-news-impact-rating-of-0-13.html.
Female Health Company (The) Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.